SUBLOCADE(TM) (Buprenorphine Extended-Release) is Now Available as First and Only Monthly Injectable Buprenorphine in the U.S. to Treat Patients with Moderate to Severe Opioid Use Disorder

Indivior launches new support services dedicated to helping streamline the access process on behalf of patients SLOUGH, England and RICHMOND, Va., March 1, 2018 -- (Healthcare Sales & Marketing Network) -- Indivior PLC (LON: INDV) today announced that ... Biopharmaceuticals, FDA, Product Launch Indivior, SUBLOCADE, buprenorphine, opioid use disorder
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news